Opendata, web and dolomites

Ru4EYE SIGNED

Ruthenium-based photoactivated chemotherapy against eye cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Ru4EYE project word cloud

Explore the words cloud of the Ru4EYE project. It provides you a very rough idea of what is the project "Ru4EYE" about.

complete    difficult    proof    innovative    models    model    ru    phototherapy    photoactivated    appealing    capital    breakage    photochemical    action    start    venture    relatively    biological    metastasis    reaction    ru4eye    solution    agents    vision    poc    2d    monolayers    bond    translation    clinical    patient    form    rare    clinics    patients    irradiation    zebrafish    save    nature    risky    exist    melanoma    preserve    presentation    diseases    performed    accelerate    bioactive    treat    protecting    toxicity    mouse    starting    driving    um    always    site    spheroids    activation    independent    evaluation    removable    therapeutic    hypoxic    3d    kill    dioxygen    erc    treatment    disease    selectively    cells    oxygen    translational    mechanism    photosensitive    efficacy    series    tumor    eye    death    grant    agent    solutions    cytotoxic    group    trials    positive    market    vitro    malignancy    light    normoxic    vivo    cancer    uveal    chemotherapy    xenografts    compounds    pact    liver    first    ruprolight    appears    drug    embryo    completion   

Project "Ru4EYE" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT LEIDEN 

Organization address
address: RAPENBURG 70
city: LEIDEN
postcode: 2311 EZ
website: www.universiteitleiden.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2021-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT LEIDEN NL (LEIDEN) coordinator 150˙000.00

Map

 Project objective

The Ru4EYE PoC proposal will develop the first pre-clinical evaluation of Ru-based PACT compounds in uveal melanoma (UM) model. UM is a rare malignancy of the eye. Although treatment against UM do exist, they do no always preserve vision or the eye, and often lead to patient death via metastasis to the liver. A better treatment that would save vision, the eye, and the patient, is looked after. UM appears as an appealing disease for photoactivated chemotherapy (PACT), a new form of phototherapy developed within my ERC Starting Grant RuProLight. PACT agents are photosensitive compounds that can kill cancer cells selectively under the action of light. In PACT dioxygen does not need to be present at the site of light irradiation because the mechanism of photochemical activation is an oxygen-independent bond breakage reaction between a bioactive, cytotoxic agent, and a light-removable protecting group. Innovative therapeutic solutions such as PACT are typically difficult to bring to the market because of the risky nature of drug development and the funding required for clinical trials. The vision in this grant proposal is that positive results on a rare form of cancer such as uveal melanoma could not only offer a relatively short-term solution to uveal melanoma patients, but also accelerate translation of Ru-based PACT to the clinics by driving developments for other diseases as well. The biological testing of Ru-based PACT compounds will be performed in a complete series of translational cancer models: from in vitro (2D monolayers of normoxic and hypoxic cancer cells, 3D tumor spheroids) to in vivo (xenografts in zebrafish embryo for studying metastasis formation and treatment, and mouse model for in vivo toxicity and efficacy). The aim is to develop a pre-clinical proof-of-concept that PACT can be used to treat uveal melanoma, so that presentation to venture capital and clinical testing can start quickly after completion of the project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RU4EYE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RU4EYE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More  

InsideChromatin (2019)

Towards Realistic Modelling of Nucleosome Organization Inside Functional Chromatin Domains

Read More  

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More